IRF9 and B-cell non-Hodgkin lymphoma: STAT3 inhibition also synergized with inducers of type I IFN, a downstream effector of the cGAS-STING pathway, to effectively inhibit B cell lymphoma growth, possibly by alleviating the suppressive effects of STAT3 on IRF7, IRF9, STAT1, and STAT2 expression [72].